Context
Recently, the Union Finance Minister, during the presentation of the Union Budget 2026-27, announced the launch of the Biopharma SHAKTI initiative to transform India into a global manufacturing hub for biopharmaceuticals. This move comes as a strategic response to India’s shifting disease profile, where non-communicable diseases (NCDs) like cancer and diabetes now account for a significant portion of the national health burden.
What is Biopharma SHAKTI?
The Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) is a flagship national initiative designed to bolster the domestic ecosystem for high-value biopharmaceutical products.
2. Key Features and Financial Outlay
- Budgetary Allocation: The government has proposed a total outlay of ₹10,000 crore over a period of five years.
- Targeted Goal: The initiative aims to capture 5% of the global biopharmaceutical market share, transitioning India from a “pharmacy of the world” (volume-based) to a global innovation hub (value-based).
- Nodal Ministry: It is steered by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers.
3. Strategic Focus: Biologics and Biosimilars
The scheme prioritizes the domestic production of complex medical products:
- Biologics: These are medicines derived from living organisms (cells, tissues, or microorganisms) rather than chemical synthesis. Examples include vaccines, gene therapies, and monoclonal antibodies.
- Biosimilars: These are “highly similar” versions of already approved biological medicines. They provide cost-effective alternatives to expensive branded biologics once patents expire.
4. Institutional and Infrastructure Strengthening
- NIPER Network: The plan includes the establishment of three new National Institutes of Pharmaceutical Education and Research (NIPERs) and the upgradation of seven existing ones to create a specialized workforce.
- Clinical Trial Ecosystem: The government intends to develop a network of over 1,000 accredited clinical trial sites across India to facilitate faster and ethical human trials.
- Regulatory Reform: The Central Drugs Standard Control Organisation (CDSCO) will be strengthened with a dedicated Scientific Review Cadre and specialists to align Indian approval timelines with global standards.
5. Innovation and Startup Support
The initiative focuses on providing early-stage innovation funding and structured equity support to help startups move from “concept to commercialization.”
- It seeks to foster collaboration between academia, research institutions, and the private industry to reduce the gestation period for new drug development.
Q. With reference to the 'Biopharma SHAKTI' initiative, recently seen in the news, consider the following statements:
1. It aims to develop India as a global manufacturing hub specifically for traditional Ayurvedic medicines and herbal formulations.
2. The initiative proposes the establishment of a dedicated "Scientific Review Cadre" within the Central Drugs Standard Control Organisation (CDSCO).
3. It has a total financial outlay of ₹10,000 crore spread over a period of ten years.
Which of the statements given above is/are correct?
A) 1 and 2 only
B) 2 only
C) 2 and 3 only
D) 1, 2 and 3
Answer: B
Solution:
• STATEMENT 1 INCORRECT: While the budget supports AYUSH, Biopharma SHAKTI specifically focuses on biologics and biosimilars (medicines from living organisms), not traditional Ayurvedic formulations.
• STATEMENT 2 CORRECT: To meet global standards and speed up approvals, the scheme proposes a Scientific Review Cadre and specialists within the CDSCO.
• STATEMENT 3 INCORRECT: The financial outlay of ₹10,000 crore is for a period of five years, not ten years.
